Interim Report January - June 1999

INTERIM REPORT JANUARY - JUNE 1999 * Sales increased by 4%. * Strong recovery in Japan led to a sales increase of 34% in Asia-Pacific. * Expansion of the sales and marketing organization, primarily in Japan, was the main reason for the decrease of earnings per share by 5%. * Successful entry into drug discovery applications with BIACORE3 000 - increased efforts initiated. * For the full-year 1999, a sales increase in line with the earlier forecast is expected, i.e. in the range of 10%. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/07/16/19990716BIT00250/bit0001.doc http://www.bit.se/bitonline/1999/07/16/19990716BIT00250/bit0002.pdf

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: www.biacore.com

Subscribe